Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of “Moderate Buy” from Analysts

Gilead Sciences, Inc. (NASDAQ:GILD) has been assigned a consensus rating of “Moderate Buy” from the twenty-seven research firms that are currently covering the stock, MarketBeat.com reports. Eleven equities research analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $97.96.

Several research firms have commented on GILD. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Truist Financial upped their target price on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Finally, Piper Sandler lifted their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 453,734 shares of company stock worth $41,902,086. Corporate insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors have recently modified their holdings of GILD. Lantz Financial LLC grew its holdings in Gilead Sciences by 3.5% during the 2nd quarter. Lantz Financial LLC now owns 24,920 shares of the biopharmaceutical company’s stock worth $1,710,000 after acquiring an additional 840 shares during the period. Choreo LLC grew its stake in shares of Gilead Sciences by 356.7% during the second quarter. Choreo LLC now owns 45,501 shares of the biopharmaceutical company’s stock worth $3,123,000 after purchasing an additional 35,538 shares during the period. Daiwa Securities Group Inc. increased its holdings in Gilead Sciences by 5.2% in the second quarter. Daiwa Securities Group Inc. now owns 215,091 shares of the biopharmaceutical company’s stock valued at $14,758,000 after purchasing an additional 10,703 shares during the last quarter. Headlands Technologies LLC lifted its stake in Gilead Sciences by 74.5% in the second quarter. Headlands Technologies LLC now owns 24,049 shares of the biopharmaceutical company’s stock valued at $1,650,000 after buying an additional 10,267 shares during the period. Finally, Garrison Point Advisors LLC lifted its stake in Gilead Sciences by 4.1% in the second quarter. Garrison Point Advisors LLC now owns 3,888 shares of the biopharmaceutical company’s stock valued at $267,000 after buying an additional 154 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 1.5 %

Shares of Gilead Sciences stock opened at $92.38 on Thursday. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $98.90. The company’s fifty day simple moving average is $91.96 and its 200-day simple moving average is $83.69. The company has a market cap of $115.13 billion, a price-to-earnings ratio of 1,026.44, a PEG ratio of 2.24 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the business posted $2.29 EPS. As a group, sell-side analysts expect that Gilead Sciences will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.